GenoMed Adds Joel V. Brill, MD to Business Development Advisory Board
CONTACT: GenoMed Inc. David W. Moskowitz, MD, MA, FACP
(314) 983-9933 dwmoskowitz@genomedics.com
ST. LOUIS, MO. – September 15, 2004 – GenoMed, Inc. (Pink Sheets: GMED), a translational medical genomics company that finds disease-causing genes in order to improve patient outcomes, announced today that it has named Joel V. Brill MD FACG to its newly created Business Development Advisory Board. Dr. Brill is a national expert in predictive modeling and physician reimbursement.
Dr. Brill is Chief Medical Officer of Predictive Health, LLC, in Phoenix, Arizona. Board certified in Internal Medicine and Gastroenterology, Dr. Brill is nationally recognized for his expertise in coding and reimbursement methodologies and positioning companies for reimbursement. Dr. Brill works extensively with payors on coverage and reimbursement issues and serves on the Pharmacy & Therapeutic Committees for several large insurance carriers.
Dr Brill is a Clinical Assistant Professor at the University of Arizona School of Medicine. He serves on several editorial boards and is a reviewer for Formulary Magazine. He has held management positions with Blue Shield of California, TriWest HealthCare Alliance, ValueOptions and Prudential Health Care. Dr. Brill is certified by the American Board of Quality Assurance and Utilization Review Physicians.
Said Dr. Dennis Robbins, Chairman of GenoMed's Business Development Advisory Board, "GenoMed has strengthened its position by adding national experts in policy, ethics, reimbursement, predictive modeling and outcomes. We expect the impact of these thought leaders and centers of influence will not only distinguish GenoMed from other genomics companies but also stimulate a dramatic increase in visibility and interest. We are committed to growth in larger markets and positioning for extensive targeted business development by translating knowledge and insight into dramatically improved clinical outcomes and high quality customized solutions."
Added Dr. David Moskowitz, GenoMed's Chairman and CEO, "I am delighted to welcome Dr. Brill to our Business Development Advisory Board. Having the right strategies for coding and reimbursement can make all the difference in a product's successful introduction into the healthcare system. Dr. Brill is an expert in the world of medical finance."
About GenoMed
GenoMed is leading the clinical revolution which medical genomics has already made possible. GenoMed is a Next Generation DM(TM) company whose mission is to improve clinical outcomes by identifying the genetic pathways that cause disease. GenoMed is currently marketing its protocol for delaying complications like kidney failure due to high blood pressure and diabetes. Eighty million Americans are at increased risk for kidney failure. GenoMed is also marketing its method for delaying emphysema, which 3 million Americans have, and another 60 million smokers are at increased risk of getting.
This summer GenoMed is coordinating nation-wide treatment for West Nile virus using the Company's patent-pending protocol, which exploits already existing, FDA-approved drugs. Anyone can enroll simply by clicking on the "West Nile trial" link at genomed.com.
. |
